Clinical review

Leishmaniasis: new approaches to disease control

Clive R Davies, head of disease control and vector biology unit ^a, Paul Kaye, professor of cellular immunology ^a, Simon L Croft, reader in parasitology ^a, Shyam Sundar, head of department ^b. 

^a Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, ^b Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India

Correspondence to: C R Davies clive.davies{at}lshtm.ac.uk

Leishmaniasis is one of the major infectious diseases affecting the poorest regions of the world, but new developments in diagnosis, treatment, and control offer some fresh hope

The leishmaniases afflict the world's poorest populations. Among the two million new cases each year in the 88 countries where the disease is endemic (fig 1), it is estimated that 80% earn less than $2 a day. Human infections with Leishmania protozoan parasites, transmitted via the bite of a sandfly, cause visceral, cutaneous, or mucocutaneous leishmaniasis. The global burden of leishmaniasis has remained stable for some years, causing 2.4 million disability adjusted life years (DALYs) lost and 59 000 deaths in 2001.¹ Neglected by researchers and funding agencies, leishmaniasis control strategies have varied little for decades, but in recent years there have been exciting advances in diagnosis, treatment, and prevention. These include an immunochromatographic dipstick for diagnosing visceral leishmaniasis; the licensing of miltefosine, the first oral drug for visceral leishmaniasis; and evidence that the incidence of zoonotic visceral leishmaniasis in children can be reduced by providing dogs with deltamethrin collars. There is also hope that the first leishmaniasis vaccine will become available within a decade. Here we review these developments and identify priorities for research.

Summary points Simple and rapid diagnostic tools for leishmaniasis will soon be widely available A new range of affordable and effective treatments, including oral drugs, are coming on line The development of drug resistance is a major concern and needs strategic plans New methods of applying insecticides for preventing leishmaniasis are likely to take the place of house spraying and (for zoonotic visceral leishmaniasis) dog culling Strategies need to be developed to optimise progression of vaccine candidates to phase I trials Current research effort and resources should prioritise visceral leishmaniasis in the Sudan and Indian subcontinent, where the burden of leishmaniasis is greatest

	Methods

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

This review is based on our personal knowledge of the subject combined with a literature search on the Entrez-PubMed site.

	Diagnosis

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

Visceral leishmaniasis
The gold standard for diagnosing visceral leishmaniasis is parasite identification in tissue smears, with splenic aspirate being more sensitive than bone marrow or lymph node aspirates. However, difficulties in obtaining and examining tissues mean that serological methods are increasingly being used.

The direct agglutination test, in which stained parasites are agglutinated by serum antibodies, is popular in Iran and Africa,^w1 but variation between batches and the high cost of commercially available antigen are limiting factors. In the Indian subcontinent,² but less so in Europe and Africa,^{3 w2} a rapid strip test is used to detect antibody to rK39 (a conserved antigen of L infantum) and is both sensitive (67-100%) and specific (93-100%) (fig 2). Weak responses in some patients, persistence of antibodies after cure, and presence of antibodies in some healthy individuals are inherent limitations with antibody based diagnostics.

Detection of leishmanial antigen in urine through a latex agglutination test (Katex) seems to be promising for both diagnosis and prognosis.⁴ Techniques based on polymerase chain reaction are potentially highly sensitive and specific,⁵ but they need to be made more suitable for field use in terms of cost and user skills required. In patients co-infected with HIV and visceral leishmaniasis, blood smears and culture might yield good results.^w3

Cutaneous and mucocutaneous leishmaniasis
Touch smears or culture of exudates or scrapings yield good results in the diagnosis of cutaneous leishmaniasis. From a nodule, slit skin smears are often rewarding. Tissue biopsy can be used for impression smears, culture, or animal inoculation, especially for mucocutaneous leishmaniasis. Although multiple Leishmania species sometimes coexist, species identification is unlikely to be cost effective in the field unless major treatment decisions for cutaneous leishmaniasis become species specific.

Fig 1.   Global distribution of leishmaniasis

Fig 2.   Diagnostic results from three serum samples using the rapid rK39 immuno- chromatographic dipstick test for diagnosing visceral leishmaniasis. The single band represents a negative control, while the two results with a double band reflect positive diagnoses for patients with visceral leishmaniasis. This user friendly test is now widely used in Nepal and India

	Treatment

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

For six decades, long parenteral courses of pentavalent antimonial (Sb^v) drugs have been used for both visceral and cutaneous leishmaniasis. The second line drugs amphotericin and the less frequently used pentamidine isetionate are toxic. The difficulties of treatment are exacerbated by the spread of resistance to antimony in India⁶ and the intractability of the disease to all drugs in patients co-infected with HIV.^w3 In most endemic countries the use of some excellent treatments, notably liposomal amphotericin (AmBisome) for visceral leishmaniasis, is limited by patients' inability to pay.⁷

Visceral leishmaniasis
Concerns about treatment failure for visceral leishmaniasis are exacerbated by geographical variations in antimonial treatment regimens, severity of disease, and sensitivity of Leishmania species. In north Bihar (India) there is clear evidence of acquired resistance of L donovani to antimonials,^w4 with up to 60% failure rate with treatment.⁶

Amphotericin B has been a standby treatment during this developing crisis^w5; the drug can be used in short courses and gives >90% cure rate.⁷ In addition, the aminoglycoside paromomycin, effective in phase II trials,⁸ is likely to be approved after a pivotal phase III study is completed. However, it is the alkylphosphocholine miltefosine (fig 3), first developed as an anticancer drug and which can be taken orally, that offers the most hope. In a series of trials this drug achieved a 94% cure rate at doses of about 2.5 mg/kg (100 mg/day for four weeks) even among patients with antimony resistant disease.^{9 w6} Miltefosine was registered for treating visceral leishmaniasis in India in March 2002. Subsequent trials in children have returned similar results. Because of its teratogenic potential, this drug should be used with caution in women of childbearing age. Another potential oral drug sitamaquine, an aminoquinoline, lacked a linear correlation between dose and cure rates and had an unsatisfactory safety and efficacy profile.^w7

Fig 3.   Children taking miltefosine, the first oral drug for visceral leishmaniasis, which was registered in India in March 2002. Trials indicate that this drug is highly effective, even against antimony resistant cases

HIV co-infections with L infantum and occasionally cutaneous leishmaniasis have proved difficult to treat, with over 60% failure rate after treatment with most antileishmanial drugs used either alone or in combination.^w8 HAART (highly active antiretroviral therapy) has some effect on the relapse rate.¹⁰

Cutaneous leishmaniasis
Over 90% of cases of cutaneous leishmaniasis (irrespective of the parasite species responsible) heal spontaneously within 3-18 months, and the rationale for drug use and determination of drug efficacy are different from those for visceral leishmaniasis. A three week course of antimonial drug is the most common treatment, especially in patients with disfiguring or relapsing cutaneous or mucocutaneous leishmaniasis.^w9

Trials with paromomycin ointments indicate considerable potential for treating cutaneous leishmaniasis (box 2). Imiquimod, an immunomodulator for genital warts, produced 90% cure rate when the ointment was used in conjunction with antimonials in 12 patients with cutaneous leishmaniasis in Peru who had not responded to antimony alone.¹¹ The potential of this approach is yet to be fully exploited.

Oral drugs have also shown promise. In an open label study in Colombia four weeks' treatment with miltefosine, 133 mg and 150 mg daily cured 100% and 89% of patients respectively.¹² For 20 years there has been interest in antifungal azoles for treating leishmaniasis, based on both microbial organisms having ergosterol as their predominant sterol. Most trials have been limited, and results are equivocal. Indications from controlled clinical trials are that ketoconazole has some potential against L mexicana infection,^w13 and recently fluconazole 200 mg/day for six weeks led to healing of cutaneous leishmaniasis (L major) in 79% of patients compared with 34% with placebo.¹³

	Vector and reservoir control

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

Insecticide spraying of houses
Spraying houses with insecticide is the most widely used intervention for controlling sandflies that are endophilic (rest mostly indoors after feeding). House spraying with the pyrethroid lambdacyhalothrin reduced the odds of cutaneous leishmaniasis in Kabul by 60%¹⁴ and reduced the risk of cutaneous leishmaniasis in the Peruvian Andes by 54%.¹⁵ Both trials measured protection at the household level, and it remains unclear under what circumstances "blanket spraying" of all houses in a village would have an additional mass effect on sandfly populations.^w14 Such evaluations are crucial for the cost effective targeting of house spraying. For example, in Sao Paulo State (Brazil) spraying against sandflies is activated by the reporting in a municipality of more than two cases of cutaneous leishmaniasis in a single year.^w15 Sustainability is vital, as cessation of spraying campaigns invariably leads to the re-emergence of leishmaniasis to pre-control levels.^w16

Bed nets
Where sandflies are endophagic (mainly feed indoors) and most active when people are asleep, bed nets provide considerable protection. For example, a case-control study in Nepal showed that people using untreated nets were 70% less likely to develop visceral leishmaniasis than people without nets.¹⁶ Protection provided by wide mesh nets is enhanced by treating them with pyrethroidsreducing sandfly biting rates by 64%-100%.^{w17 w18} There is also evidence from Colombia that sandfly bites are not diverted to people sleeping outside insecticide treated nets: "unprotected" people in the same room as someone sleeping under a deltamethrin treated net received 42% less sandfly bites than people in houses without nets.^w17 After encouraging, but inconclusive, results from small scale epidemiological trials in Iran,^w19 Syria,¹⁷ and Sudan (D El Naiem personal communication), the household trial in Kabul showed that permethrin treated nets were no less effective than house spraying, reducing cutaneous leishmaniasis risk by 65%.

Fig 4.   This deltamethrin treated collar (Scalibor, InterVet, Boxmeer, Netherlands) provides dogs (the reservoir host of L infantum) with long term protection against sandfly bites and canine visceral leishmaniasis. Field trials in Iran show that providing all dogs in a community with collars also protects children against L infantum infection

This result cannot be extrapolated elsewhere, as effectiveness of insecticide treated bed nets is determined by local sandfly behaviour. It is unclear, for example, whether the provision of about 300 000 such nets by Médecins Sans Frontières in eastern Sudan during 1998-2001 substantially reduced the incidence of visceral leishmaniasis (R Davidson personal communication). To our knowledge, insecticide treated nets have not been introduced outside the Sudan by any leishmaniasis control programme (as opposed to a trial) except in Afghanistan and Pakistan, where they have been provided by HealthNet to patients with active cutaneous lesions (L tropica). Their aim is not to protect the patients but to block transmission, as L tropica is transmitted anthroponotically. As with house spraying, it is unclear whether the widespread use of insecticide treated nets will have any mass effect, as there was no detectable impact on sandfly abundance in either the Iranian or Syrian trial.^{17 w19} However, a recent cluster randomised trial in Venezuela showed that village-wide treatment of loosely hanging curtains with lambdacyhalothrin significantly reduced indoor sandfly abundance and eliminated cutaneous leishmaniasis risk.^w20

View larger version (42K): [in this window] [in a new window]   Fig 5.   The life cycle of Leishmania parasites and targets for vaccination. Leishmania cycle between sandfly vectors, where they exist as multiplicative "procyclic" promastigotes and infective "metacyclic" promastigotes, and their mammalian host, where they exist as intracellular amastigotes living predominantly in the phagolysosome of macrophages. After initial infection, amastigotes may replicate for some time before triggering an inflammatory and adaptive immune response. The latter requires migration of dermal dendritic cells to draining lymph nodes and their presentation of antigens derived from Leishmania to both CD4 and CD8 T cells. These then accumulate in the developing inflammatory lesion and promote parasite destruction by producing cytokines able to activate macrophage defences. Vaccination may promote these responses if vaccine antigens are delivered in an appropriate way to trigger both T cell subsets. Alternatively, immune responses against sandfly saliva may cause rapid local inflammation not conducive to parasite survival or block the function of salivary immunomodulators. Finally, host immune responses may target essential steps in parasite development within the sandfly (such as attachment to the fly midgut)

Control of zoonotic infection
In Brazil about 200 000 houses are sprayed and 20 000 dogs are culled each year to prevent zoonotic visceral leishmaniasis. After annual surveys in endemic regions, dogs are culled if their blood samples are diagnosed positive by immunofluorescence. Although experimental trials indicate that dog control may reduce Leishmania incidence in both dogs and children,¹⁸ concerns over the delays between sampling, diagnosis, and culling, and a failure to reduce the number of notified cases, have led to scepticism of the effectiveness of the Brazilian control programme.^w21 More effective diagnostic tools may allow culling without delay,^w22 but a recent trial of the rK39 dipstick test (see above) showed poor specificity (<75%) for diagnosing infected dogs.¹⁹

In the absence of a reliable and rapid tool for detecting infected dogs, alternative control strategies for zoonotic visceral leishmaniasis are being sought. Dipping dogs in insecticide^w23 or applying topical insecticide lotions²⁰ can substantially reduce sandfly bites on dogs and so protect them from infection, but this strategy requires regular retreatment as the insecticidal effect is short lived. However, a novel method for topical application of insecticide on dogs enables the insecticidal effect to persist for up to eight months.^w24 Experimental trials have consistently shown that deltamethrin treated collars (fig 4) reduce by up to 90% the proportion of sandflies that take a blood meal and survive.^{20 w24} Widespread use of these collars with domestic dogs in Italy reduced their risk of being infected by L infantum,^w25 and a matched cluster randomised trial in Iran showed that, not only was the odds of infection in dogs reduced by 54%, but children living in the treated villages had significantly less risk of infection as well (odds ratio 0.57).²¹

	Progress in vaccine development

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

Of all the parasitic diseases, leishmaniasis is considered the most likely to succumb to vaccination. The parasite has a particularly simple life cycle (fig 5), resolution of primary cutaneous leishmaniasis usually results in resistance to re-infection, and studies in experimental models have suggested simple CD4 Th1-type, cell mediated resistance (involving activation of macrophage killing mechanisms by T lymphocyte-derived interferon ). In experimental models of cutaneous leishmaniasis, in which CD4 Th1 responses are driven towards a polarised Th1 response, protection can indeed be achieved by vaccination, although this rarely results in complete protection from development of lesions. Such vaccines, however, stimulate only poor memory, and protection wanes after a few weeks.²² In primate studies and clinical trials they show immunogenicity but rarely give appreciable protection. ^{23 24 w26}

Educational resources TDR. Leishmaniasis. www.who.int/tdr/diseases/leish (accessed 13 Dec 2002) Communicable Disease Surveillance and Response (CSR). Leishmaniasis. www.who.int/emc/diseases/leish (accessed 13 Dec 2002) World Health Organization. Leishmaniasis (kala azar). www.who.int/health-topics/leishmaniasis.htm (accessed 13 Dec 2002) CDC Division of Parasitic Diseases. Leishmania infection (leishmaniasis). www.cdc.gov/ncidod/dpd/parasites/leishmania (accessed 13 Dec 2002)Also a useful educational resource for patients Wellcome Trust. Leishmaniasis (Topics in International Health) [CD Rom]. Wallingford: CABI Publishing, 2000. World Health Organization. Manual on visceral leishmaniasis control. Geneva: Division of Control of Tropical Diseases, 1996. (WHO/LEISH/96.40.) Osman OF, Kager PA, Oskam L. Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects. Trop Med Int Health 2000;5:553-62 Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6:849-54 Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001;6:899-905. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull WHO 2001;79:388-93 Schallig HD, Oskam L. Review: molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Int Health 2002;7:641-51 Guerin PJ, Olliaro P, Sundar S, Boelart M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501

In the past three to four years our view of the requirements for vaccine induced immunity has changed. A major paradigm shift reflects the role of CD8 T cells. New models of cutaneous leishmaniasis indicate that CD8 cells are vital for primary resistance.²⁴ It has also been recognised that CD8 cells are required for the maintenance of long term vaccine induced immunity. Although the capacity to induce CD8 cell responses is a feature of DNA vaccines, this has also been shown for some protein based vaccines.²⁵

Although clinical trials continue with crude autoclaved L major, some defined protein antigens have been identified, sometimes rationally, sometimes by serendipity.²² The Leishmania Genome Project (www.sanger.ac.uk/Projects/L_major/) provides an impetus for immunisation with an expression library of the parasite to screen all expressed proteins.²⁶ Recent advances in combining vaccine delivery systems in so called prime-boost schedules are also being tested in models of cutaneous leishmaniasis.^w27 The bottleneck imposed by producing materials to the standards of good laboratory practice (GLP) and good manufacturing practice (GMP) and the costs of trials are major hurdles in taking any of these discoveries further. A $15m (£9.4m; 15.1m) award from the Bill and Melinda Gates Foundation to support vaccine development at the Infectious Disease Research Institute in Seattle is a welcome boost. A recombinant vaccine (Trifusion, a fusion peptide of the leishmanial antigens LMST11, TSA, and LeIF) is being prepared for clinical trials, and the recent observation that Trifusion, given in combination with immunostimulatory CpG oligodeoxynucleotides, stimulated CD4 and CD8 cells and long term immunity is encouraging.²⁵

Rapid progress in vaccine development is also hindered when natural challenge is the only means of validation. In this regard, the resurrection of "leishmanisation" sponsored by the World Health Organization and the Special Programme for Research and Training in Tropical Diseases (TDR) is a major step forward. Leishmanisation (active infection to produce natural resistance) was once common in the Middle East and eastern Europe to minimise the impact of scarring but was largely discontinued because of unacceptable lesions in some recipients. However, scientists in Iran have now produced L major stabilates (populations stored in a genetically stable and viable condition) to GLP standard, which should produce consistent and acceptable lesions. Leishmanisation may thus provide an ethically acceptable means of live vaccine challenge in endemic areas.

For visceral leishmaniasis, the situation remains less promising, and, although there are concerns about whether the same vaccine will work for all leishmaniases, human trials of vaccines against visceral leishmaniasis are likely to follow only from successful outcomes of those against cutaneous leishmaniasis, or as in the Sudan, on a compassionate basis.²⁷ Recent reports suggest some progress is being made in vaccines for canine visceral leishmaniasis.^{28 w30}

	Footnotes

Competing interests: CRD has been reimbursed by InterVet, manufacturer of Scalibor, for attending conferences. SLC was paid by Zentaris, manufacturer of miltefosine, for writing part of the dossier for drug registration.

References w1-w30 are listed on bmj.com

	References

Top Methods Diagnosis Treatment Vector and reservoir control Progress in vaccine development References

1.	World Health Organization. Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. In: The world health report. Geneva: WHO, 2002:192-197. (www.who.int/whr/2002/whr2002_annex3.pdf)
2.	Sundar S, Reed SG, Singh VP, Kumar PCK, Murray HW. Rapid accurate field diagnosis of visceral leishmaniasis. Lancet 1998; 351: 563-565[CrossRef][ISI][Medline].
3.	Zijlstra EE, Nur Y, Desjeux P, Khalil EA, el Hassan AM, Groen J. Diagnosis of visceral leishmaniasis with the recombinant k39 strip test: experience from Sudan. Trop Med Int Health 2001; 6: 108-113[CrossRef][ISI][Medline].
4.	Attar ZJ, Chance ML, el Safi S, Carney J, Azazy A, El Hadi M, et al. Latex agglutination test for detection of urinary antigens in visceral leishmaniasis. Acta Trop 2001; 78: 11-16[CrossRef][ISI][Medline].
5.	Martin Sanchez J, Lopez-Lopez MC, Acedo-Sanchez C, Castro-Fajardo JJ, Pineda JA, Morillas-Marquez F. Diagnosis of infection with Leishmania infantum using PCR-ELISA. Parasitology 2001; 122: 607-615[Medline].
6.	Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-1107[CrossRef][ISI][Medline].
7.	Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-422[Abstract/Free Full Text].
8.	Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, et al. Randomised control trial of aminosidine vs Sbv for treating visceral leishmaniasis in north Bihar, India. BMJ 1998; 316: 1200-1205[Abstract/Free Full Text].
9.	Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-1800[Abstract/Free Full Text].
10.	De La Rosa R, Pineda JA, Delgado J, Macias J, Morillas F, Mira JA, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40: 762-767[Abstract/Free Full Text].
11.	Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847-1851[CrossRef][ISI][Medline].
12.	Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: e57-e61.
13.	Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-895[Abstract/Free Full Text].
14.	Reyburn H, Ashford R, Mohsen M, Hewitt S, Rowland M. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000; 94: 361-366[CrossRef][Medline].
15.	Davies CR, Llanos-Cuentas EA, Campos P, Monge J, Leon E, Canales J. Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94: 631-636[CrossRef][Medline].
16.	Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000; 63: 184-188[Abstract].
17.	Tayeh A, Jalouk L, Al-Khiami AM. A cutaneous leishmaniasis control trial using pyrethroid-impregnated bednets in villages near Aleppo, Syria. Geneva: World Health Organization, 1997. (WHO/LEISH/97.41.)
18.	Ashford DA, David JR, Freire M, David R, Sherlock I, Eiulalio MC, et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 1998; 59: 53-57[Abstract].
19.	Reithinger R, Quinnell RJ, Alexander B, Davies CR. Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and PCR. J Clin Microbiol 2002; 40: 2352-2356[Abstract/Free Full Text].
20.	Reithinger R, Teodoro U, Davies CR. A comparative trial of topical insec-ticide treatments to protect dogs from bites of sandfly vectors of leishmaniasis. Emerg Infect Dis 2001; 7: 872-876[Medline].
21.	Mazloumi Gavgani AS, Hodjati MH, Mohite H, Davies CR. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 2002; 360: 374-379[Medline].
22.	Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14: 229-243[Abstract/Free Full Text].
23.	Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 163: 4481-4488[Abstract/Free Full Text].
24.	Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, et al. . CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168: 3992-4000[Abstract/Free Full Text].
25.	Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002; 195: 1565-1573[Abstract/Free Full Text].
26.	Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immunol 2001; 69: 4719-4725[Abstract/Free Full Text].
27.	Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356: 1565-1569[CrossRef][Medline].
28.	Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 2001; 100: 87-103[CrossRef][Medline].